Analysis of Wegener's Granulomatosis Responses to Rituximab: Current Evidence and Therapeutic Prospects.

Aouba A, Pagnoux C, Bienvenu B, Mahr A, Guillevin L.
Department of Internal Medicine and the French Vasculitis Study Group, Assistance Publique-Hôpitaux de Paris, Université Paris, 5-René-Descartes, Hôpital Cochin, 27, rue du faubourg Saint-Jacques, 75679, Paris Cedex 14, France, achille.aouba@wanadoo.fr.

Available data on small numbers of patients with refractory and/or relapsing Wegener's granulomatosis support very good overall outcomes with rituximab, an anti-CD20 biotherapy targeting B cells, in combination with ongoing immunosuppressants, apparently independently of antineutrophil cytoplasm antibody (ANCA) status.

Rest of the information is here.

My analysis: Another drug that will help WG patients.